Completed PHASE4 INTERVENTIONAL 2-arm NCT05154383

Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression (INFLUOMICS)

Sponsor: Centre Hospitalier Annecy Genevois

Interventions Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)

Updated 4 times since 2022 Last updated: Aug 5, 2022 Started: Nov 15, 2021 Primary completion: Jul 21, 2022 Completion: Jul 21, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05154383, this PHASE4 trial focuses on Vaccine Reaction and remains completed. Sponsored by Centre Hospitalier Annecy Genevois, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE4

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Annecy Genevois
Euraxi Pharma
Eurofins Optimed
Hospices Civils de Lyon
Institut National de la Santé Et de la Recherche Médicale, France
Sanofi Pasteur, a Sanofi Company

Data source: Centre Hospitalier Annecy Genevois

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Annecy, France
• Chambéry, France